Details for Patent: 5,744,123

Title:	Aerosol formulations containing P134a and particulate medicaments
Abstract:	This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Inventor(s):	Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3)
Assignee:	Glaxo Group Limited (London, GB2)
Filing Date:	Jun 05, 1995
Application Number:	08/462,558
Claims:	1. A pharmaceutical formulation consisting essentially of (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, wherein one of the said one or more medicaments is a bronchodilator selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]m ethyl]benzenemethanol or a physiologically acceptable salt thereof. 2. A formulation as claimed in claim 1 which is free of surfactant. 3. A formulation as claimed in claim 1 wherein said medicament is pirbuterol. 4. A formulation as claimed in claim 1 which contains two or more particulate medicaments. 5. A formulation as claimed in claim 1 which comprises a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament. 6. A formulation as claimed in claim 1 which comprises a particulate bronchodilatory medicament and a particulate anti-allergic medicament. 7. A formulation as claimed in claim 1 which comprises isoprenaline and cromoglycate or a physiologically acceptable salt thereof. 8. A formulation as claimed in claim 1 which contains 0.01 to 1% w/w of medicament relative to the total weight of the formulation. 9. A formulation as claimed in claim 1 which has a respirable fraction of 20% or more by weight of medicament. 10. A pharmaceutical aerosol formulation consisting of (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, wherein said one of the one or more medicaments is a bronchodialtor selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]m ethyl]benzenemethanol or a physiologically acceptable salt thereof. 11. A formulation as claimed in claim 10 wherein said medicament is pirbuterol. 12. A formulation as claimed in claim 10 which contains two or more particulate medicaments. 13. A formulation as claimed in claim 10 which comprises a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament. 14. A formulation as claimed in claim 10 which comprises a particulate bronchodilatory medicament and a particulate anti-allergic medicament. 15. A formulation as claimed in claim 10 which comprises isoprenaline and cromoglycate or a physiologically acceptable salt thereof. 16. A formulation as claimed in claim 10 which contains 0.01 to 1% w/w of medicament relative to the total weight of the formulation. 17. A formulation as claimed in claim 10 which has a respirable fraction of 20% or more by weight of medicament.